Angela Vollstedt

Global Director, Cell & Gene Therapies Portfolio Management • Novartis

Angela Vollstedt, a seasoned professional in the pharmaceutical industry, boasts an impressive 15+ year international career marked by notable achievements. Her expertise encompasses leading pharmaceutical drug research and development, life-cycle management, and commercial manufacturing. Angela thrives on challenges and is deeply committed to driving operational excellence and innovation within fast-paced environments that demand strong business acumen and impeccable time management.

With a genuine passion for organizational growth, Angela has successfully collaborated with research scientists and executive leadership to translate cutting-edge scientific discoveries into tangible healthcare advancements. Her exceptional abilities in building robust relationships and fostering a healthy work environment have allowed her to leverage emotional intelligence and strategic thinking to facilitate constructive decision-making and open communication with C-suite executives and stakeholders at all levels.

Angela’s accomplishments in the fields of biologics, as well as cell and gene therapies research & development, are commendable. She has demonstrated a remarkable track record in delivering new medical products from early clinical development to market authorization applications and life-cycle management, while effectively managing multi-million-dollar budgets. Additionally, she has excelled in leading high-performing commercial manufacturing teams, ensuring timely customer satisfaction and preparing for successful health authority audits.

Also speaking

Laura Herbst

M. Sc. Research Fellow • Fraunhofer

John Garcia

PhD, Head of New Manufacturing Technologies • UCL

Helen Tayton-Martin

Chief Business & Strategy Officer • Adaptimmune

Event Info


Innovation Zone

Find out more about the Innovation Zone at Advanced Therapies Europe.

Advanced Therapies Investment Summit

Find out more about the Investor Pre-Day taking place 10th September 2024.